KRAS targeted for the first time (2021)
For four decades, mutations in RAS genes were considered undruggable: the proteins are smooth and lack the pockets most drugs need. Sotorasib changed that in 2021 when it won FDA approval for lung cancer driven by one specific mutation, KRAS G12C.
The drug shrank tumors in a minority of heavily pretreated lung cancer patients, and responses lasted months rather than years.
It opened a drug class. Later compounds target other RAS variants and, like daraxonrasib, are designed to work without requiring one particular mutation.
Daraxonrasib belongs to that second generation. Its broad RAS reach is what makes it testable in pancreatic cancer, where most tumors are driven by RAS mutations but not the G12C variant.
